Seattle’s Juno Therapeutics is benefiting from its $1 billion relationship with Celgene, Juno’s CEO told shareholders at the company’s annual meeting.
“The early part of this relationship has been nothing but positive,” Hans Bishop said at the Thursday meeting.
That's good, because Juno is locked into a decade-long deal with Celegene that Bishop said prohibits it from striking similar commercial partnerships for the 10 years.
The companies, which are both developing therapies for treating…
Seattle’s Juno Therapeutics is benefiting from its $1 billion relationship with Celgene, Juno’s CEO told shareholders at the company’s annual meeting.
“The early part of this relationship has been nothing but positive,” Hans Bishop said at the Thursday meeting.
That's good, because Juno is locked into a decade-long deal with Celegene that Bishop said prohibits it from striking similar commercial partnerships for the 10 years.
The companies, which are both developing therapies for treating…